Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Uscom Limited ( (AU:UCM) ) is now available.
Uscom Limited reported a marginally positive operating cash flow of A$3,000 for the March 2026 quarter, compared with a year-to-date operating cash outflow of A$1.289 million, indicating ongoing cost pressures despite modest quarterly stability. Receipts from customers reached A$48,000 for the quarter and A$763,000 for the nine months, while staff and administration expenses remained the largest cash drains.
The company recorded minimal investing activity, with only A$11,000 spent on intellectual property in the quarter and A$13,000 year-to-date, suggesting a cautious approach to capital deployment. Financing cash flows were slightly positive at A$7,000 for the quarter and A$336,000 for the nine months, supported earlier in the year by borrowings, leaving Uscom with a small net increase in cash of A$2,000 over the period and underscoring its tight but currently stable liquidity position.
The most recent analyst rating on (AU:UCM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Uscom Limited stock, see the AU:UCM Stock Forecast page.
More about Uscom Limited
Uscom Limited is a medical technology company focused on non-invasive cardiovascular and pulmonary monitoring devices for clinical and research markets. The company targets hospitals and healthcare providers seeking advanced hemodynamic assessment tools to improve patient management, particularly in critical care and cardiology settings.
Technical Sentiment Signal: Sell
Current Market Cap: A$3.12M
See more insights into UCM stock on TipRanks’ Stock Analysis page.